Pathology: metastatic/advanced OC (mOC) - 2nd line (L2);
metastatic/advanced OC (mOC) - 2nd line (L2) | |||
JAVELIN ovarian 200 (A vs doxorubicin), 2021 | JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 | ||
avelumab alone | 1 | T1 | |
avelumab plus pegylated liposomal doxorubicin | 1 | T1 | |
pegylated liposomal doxorubicin | 0 | T0 | T0 |